跳至主要内容
临床试验/IRCT20200404046937N2
IRCT20200404046937N2已完成3 期

Evaluating the therapeutic effect of Phyllanthus Emblica on COVID 19 patients, A double blind clinical trial

Ahvaz University of Medical Sciences0 个研究点目标入组 60 人开始时间: 待定最近更新:
适应症

试验速览

阶段
3 期
状态
已完成
入组人数
60

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
18 years 至 no limit(—)
性别
All

入选标准

  • Age =18 years
  • Laboratory polymerase chain reaction (PCR) confirmed infection with COVID19
  • Lung involvement confirmed with chest imaging
  • Hospitalized with: Fever (axillar or oral temperature = 38.0°) or Respiratory rate >24/min Or Cough
  • Less than 8 days since illness onset
  • Willingness of study participant to accept randomization to any assigned treatment arm
  • Acceptance of non-participation in another study before the 28th day of the study

排除标准

  • Physician makes a decision that trial involvement is not in patients' best interest, or any condition that does not allow the protocol to be followed safely.
  • Severe liver disease
  • Known allergic reaction to Phyllanthus Emblica
  • Severe renal impairment
  • Pregnant or breastfeeding women
  • Transfer to another non-study hospital within the next 72 hours
  • Receipt of any experimental treatment for COVID 19 within the 30 days prior to the time of the screening evaluation
  • Angiotensin converting enzyme (ACE) inhibitor user

研究者

相似试验